Customize CCR1 Antibody

Description

Definition and Biological Role of CCR1 Antibody

CCR1 antibodies are immunologic reagents designed to bind specifically to CCR1, a chemokine receptor expressed on neutrophils, monocytes, lymphocytes, and eosinophils . They are used to:

Block receptor activity (e.g., inhibiting chemokine binding)
Detect CCR1 expression in tissues or cells via flow cytometry, ELISA, or immunohistochemistry
Study leukocyte trafficking in inflammatory and autoimmune diseases

Key ligands for CCR1 include CCL3 (MIP-1α), CCL5 (RANTES), and CCL15, which drive immune cell recruitment to sites of inflammation or cancer .

Cancer

Multiple Myeloma: High CCR1 expression in bone marrow plasma cells correlates with poor prognosis (HR=2.5, P<0.05) . CCR1 blockade via CCX721 reduced osteolysis and tumor burden in murine models by 60% .
Breast Cancer: CCR1 is overexpressed in invasive ductal carcinoma (mean intensity: 5.78 vs. 1.67 in normal tissue; P<0.001) . Silencing CCR1 inhibited MDA-MB-231 cell invasion in 3D models .

Autoimmune and Inflammatory Disorders

Rheumatoid Arthritis: The CCR1 inhibitor CCX354 demonstrated clinical efficacy in Phase II trials, reducing swollen joint counts by 30% (P<0.05) .
Behçet’s Disease: Anti-CCL3 antibody therapy improved symptoms in mouse models by upregulating CCR1+ cells .

Table 2: CCR1-Targeted Clinical Studies

Study Compound	Condition	Phase	Key Finding
CCX354	Rheumatoid Arthritis	II	200 mg/day reduced disease activity (ACR20: 40%)
CCX721	Multiple Myeloma	Preclinical	Inhibited osteoclast formation (IC₅₀: 0.02 nM)
BX471	Neuroinflammation	Preclinical	Reduced microglial activation in Parkinson’s models

Mechanistic Insights from Preclinical Models

CCR1 Knockout Mice: Exhibit defects in neutrophil trafficking and reduced inflammation in models of lupus nephritis and asthma .
Chemotaxis Inhibition: CCX721 blocked CCL15-induced THP-1 cell migration at 1.1 nM IC₅₀ in human serum .

Challenges and Future Directions

While CCR1 blockade shows promise, earlier efforts targeting related receptors (CCR2/CCR5) failed due to redundant chemokine pathways . Current strategies focus on:

Dual targeting of CCR1 and CXCR4 in hematologic cancers
Biomarker-driven patient stratification (e.g., CCR1 expression levels)

Product Specs

Buffer

Preservative: 0.03% ProClin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Lead Time

14-16 week lead time (made-to-order)

Synonyms

CCR1 antibody; CRR1 antibody; At3g09780 antibody; F11F8.37 antibody; F8A24.17 antibody; Serine/threonine-protein kinase-like protein CCR1 antibody; EC 2.7.11.1 antibody; Protein CRINKLY 4 RELATED 1 antibody; AtCRR1 antibody

Target Names

CCR1

Uniprot No.

Q9S7D9

Target Background

Function

This antibody targets a serine/threonine-protein kinase exhibiting low enzymatic activity.

Gene References Into Functions

Further understanding of this kinase's function is informed by research such as:

An investigation into the effects of lignin synthesis disruption on Arabidopsis thaliana cell wall assembly using a cinnamoyl-CoA reductase 1 (CCR1) knockout mutant. PMID: 19674336

Database Links

KEGG: ath:AT3G09780

STRING: 3702.AT3G09780.1

UniGene: At.40041

Protein Families

Protein kinase superfamily, Ser/Thr protein kinase family

Subcellular Location

Membrane; Single-pass type I membrane protein.

Tissue Specificity

Expressed in roots, leaves, shoot apical meristems (SAM), and floral buds.

Q&A

Here’s a structured collection of FAQs tailored to academic research scenarios for CCR1 antibodies, integrating scientific depth and methodological guidance:

Advanced Research Questions

How to reconcile conflicting data on CCR1’s role in autoimmune vs. cancer models?

Analysis framework:
- Model comparison:
  - In HSV-induced Behçet’s disease (BD), CCR1+ cell frequency correlates with symptom severity (r=0.82, p<0.01) .
  - In MC38 colorectal tumors, CCR1-KO reduces growth by 63% vs. WT (p<0.001) .
- Mechanistic divergence:
  - Autoimmunity: CCR1 mediates Th1/Th2 imbalance .
  - Cancer: CCR1+ myeloid cells secrete MMP9/VEGF promoting metastasis .

What strategies enhance CCR1 blockade efficacy in therapeutic studies?

Experimental design:
- Combination therapy: Anti-CCR1 (KM5908) + anti-PD1 reduces MC38 tumor volume by 78% vs. monotherapy (41%) .
- Timing: Administer antibodies during myeloid cell infiltration (day 3-7 post-implantation).
- Dosage table:

Model	Antibody	Effective Dose	Outcome
BD mouse	Anti-CCL3	10 mg/kg	50% symptom reduction
MC38 tumor	KM5908	15 mg/kg	63% growth inhibition

How to resolve discrepancies in CCR1 ligand binding assays?

Critical factors:
- Calcium flux vs. chemotaxis: CCL3 shows EC50=1.2 nM in calcium assays vs. 3.8 nM in migration .
- Species specificity: Mouse CCR1 has 18% divergence in extracellular domains vs. human .
- Validation checklist:
  - Confirm cross-reactivity using species-specific primers.
  - Include cyclosporin A (CCR1 inhibitor) as a control .

Data Contradiction Resolution

7. When CCR1 staining varies between flow cytometry and IHC:

Root cause analysis:
- Fixation artifacts: Methanol fixation masks CCR1 epitopes; use PFA-based methods .
- Conformational states: Surface vs. internalized CCR1 requires differential permeabilization .

8. If CCR1 blockade shows opposite effects in different cancer models:

Hypothesis testing:
- Microenvironment profiling: CMT93 metastases show 3× higher CCR1+MDSCs than primary tumors .
- Ligand screen: Test CCL3/CCL5/CCL7 levels via Luminex.

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

CCR1 Antibody